Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: A systematic review.

Abstract

INTRODUCTION:

Treatment of metastatic castration-resistant prostate cancer with conventional therapies is still not successful. Therefore, application of novel biological approaches such as immunotherapy, which appears to be more effective and less toxic, is necessary. Monoclonal antibodies against cancer specific antigens are a kind of immunotherapy that have been approved for specific types of cancer and are being investigated for prostate cancer as well. The aim of this review was to assess the effectiveness and safety of monoclonal antibodies for treatment of advanced prostate cancer.

METHOD:

According to the search strategy stated in our systematic review protocol, Scopus, Medline, TRIP, CENTRAL, ProQuest, DART and OpenGrey databases were searched. Data collection and quality assessment were done independently by two authors and any disagreements between the collected data were resolved by a third author. A meta-analysis was not feasible as there was a considerable statistical heterogeneity among the trials. Hence, this review was limited to a narrative analysis of the included studies.

RESULTS:

We found 9756 references by applying search strategy in 4 databases of journal articles and 3 databases of grey literature. We then discarded 3957 duplicate citations using Endnote software and 5143 articles due to obvious irrelevancy of their topics in primary screening. In secondary screening of 656 fulltexts, we excluded 538 articles, and finally included 12 trials in this systematic review, updated on 23 June 2017. The overall quality of the studies was fair. In general, results of this systematic review show promising advances in the treatment of prostate cancer patients with monoclonal antibodies against prostate-specific antigens with regard to PSA/disease response. Some of the studies reported pain relief after treatment as well.

CONCLUSION:

Currently, the role of immunotherapy in the treatment of advanced prostate cancer still remains debated. Although passive specific immunotherapy could be offered as a novel therapeutic option in the coming years, patients should be informed about the risks and benefits of this therapy. One of the obstacles in this review was the lack of adequate assessment of survival-related endpoints reported in the included studies. Our study provides support for further research in this field.

• Authors: Neda Khalili, Mahsa Keshavarz-Fathi, Sepideh Shahkarami, Armin Hirbod-Mobarakeh, Nima Rezaei
• Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (J Oncol Pharm Pract) Vol. 25 Issue 4 Pg. 903-917 (Jun 2019) ISSN: 1477-092X [Electronic] England
• PMID: 30348069 (Publication Type: Journal Article, Systematic Review)

Chemical References

• Antibodies, Monoclonal
• Antigens, Surface
• Antineoplastic Agents, Immunological
• FOLH1 protein, human
• Glutamate Carboxypeptidase II
• KLK3 protein, human
• Kallikreins
• Prostate-Specific Antigen

Topics

• Antibodies, Monoclonal (therapeutic use)
• Antigens, Surface (blood)
• Antineoplastic Agents, Immunological (therapeutic use)
• Glutamate Carboxypeptidase II (blood)
• Humans
• Immunotherapy (methods)
• Kallikreins (blood)
• Male
• Prostate-Specific Antigen (blood)
• Prostatic Neoplasms (blood, drug therapy)